Search
De Novo Triacylglycerol Biosynthesis TG(10:0/17:0/8:0)
smpdb.ca/view/SMP0026942MetabolicTriglycerides are the main constituents of body fat in humans and other animals, as well as vegetable fat. … (Wikipedia) De novo biosynthesis of triglycerides is also known as the phosphatidic acid pathway, and it is mainly associated with the liver and adipose tissue.
De Novo Triacylglycerol Biosynthesis TG(10:0/20:0/17:0)
smpdb.ca/view/SMP0026944MetabolicTriglycerides are the main constituents of body fat in humans and other animals, as well as vegetable fat. … (Wikipedia) De novo biosynthesis of triglycerides is also known as the phosphatidic acid pathway, and it is mainly associated with the liver and adipose tissue.
De Novo Triacylglycerol Biosynthesis TG(10:0/20:0/20:0)
smpdb.ca/view/SMP0026945MetabolicTriglycerides are the main constituents of body fat in humans and other animals, as well as vegetable fat. … (Wikipedia) De novo biosynthesis of triglycerides is also known as the phosphatidic acid pathway, and it is mainly associated with the liver and adipose tissue.
De Novo Triacylglycerol Biosynthesis TG(8:0/10:0/22:0)
smpdb.ca/view/SMP0026947MetabolicTriglycerides are the main constituents of body fat in humans and other animals, as well as vegetable fat. … (Wikipedia) De novo biosynthesis of triglycerides is also known as the phosphatidic acid pathway, and it is mainly associated with the liver and adipose tissue.
NGD-4715
go.drugbank.com/drugs/DB06027ExperimentalNGD-4715 is an investigational compound developed for the treatment of Obesity. NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.
Synonyms: 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine, 1-(5-bromo-6-methoxypyridin-2-yl)-4-[(3,4-dimethoxyphenyl)methyl]piperazineMEM 1414
go.drugbank.com/drugs/DB05888ExperimentalMEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of the brain where new memories are formed. … MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials.
Aleglitazar
go.drugbank.com/drugs/DB08915InvestigationalAleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. … Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes.
Categories: Heterocyclic Compounds, 1-RingAnthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalIt is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue … Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and
Delorazepam
go.drugbank.com/drugs/DB01511IllicitInvestigationalIt may have adverse effects such as drowsiness, and cognitive impairments such as short term memory impairment. Delorazepam is an active metabolite of the benzodiazepine known as cloxazolam. … It is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting. Lorazepam is also a major active metabolite of delorazepam.
Categories: Heterocyclic Compounds, 2-RingMitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigationalMitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … [A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953]
Synonyms: Pkr-in-1Categories: P-glycoprotein inhibitors, P-glycoprotein substrates